Fulcrum Therapeutics (FULC) FCF Margin: 2020-2024
Historic FCF Margin for Fulcrum Therapeutics (FULC) over the last 4 years, with Jun 2024 value amounting to 73.62%.
- Fulcrum Therapeutics' FCF Margin rose 245771.00% to 73.62% in Q2 2024 from the same period last year, while for Jun 2024 it was -15.29%, marking a year-over-year increase of 304892.00%. This contributed to the annual value of -3.12% for FY2024, which is 325795.00% up from last year.
- Latest data reveals that Fulcrum Therapeutics reported FCF Margin of 73.62% as of Q2 2024, which was up 102.76% from -2,667.62% recorded in Q4 2023.
- Fulcrum Therapeutics' FCF Margin's 5-year high stood at 73.62% during Q2 2024, with a 5-year trough of -8,232.88% in Q1 2023.
- In the last 3 years, Fulcrum Therapeutics' FCF Margin had a median value of -2,384.09% in 2023 and averaged -2,654.25%.
- Per our database at Business Quant, Fulcrum Therapeutics' FCF Margin tumbled by 734,735bps in 2023 and then skyrocketed by 245,771bps in 2024.
- Fulcrum Therapeutics' FCF Margin (Quarterly) stood at -480.43% in 2020, then soared by 3,802bps to -442.41% in 2021, then plummeted by 244,985bps to -2,892.26% in 2022, then soared by 22,464bps to -2,667.62% in 2023, then soared by 245,771bps to 73.62% in 2024.
- Its FCF Margin was 73.62% in Q2 2024, compared to -2,667.62% in Q4 2023 and -3,026.48% in Q3 2023.